newsfilter
← Latest News
GlobeNewswire·

NexImmune Reports First Quarter 2021 Financial Results and Recent Updates

Advancing two lead product candidates in Phase 1/2 clinical trials Completed successful $126M initial public offering (IPO) in February 2021 Additional clinical and preclinical data anticipated in the second half of 2021 GAITHERSBURG, Md., May